1.28 Questionable FDA Drug Approvals and Building a Career with Dr. Chadi Nabhan

OncologyMedicineHealth Policy
Written By Kerrington .

In this episode we critique two recent FDA drug approvals (venetoclax in combination with azacitidine or decitabine or low-dose cytarabine; glasdegib in combination with low-dose cytarabine -- both for acute myeloid leukemia)and we interview Dr. Chadi Nabhan, the Chief Medical Officer of Cardinal Health, on career transitions. The interview was taped on location at the 2018 annual conference of the American Society of Hematology in San Diego.

Kerrington .
Previous

1.29 RCT of Parachutes and Frameworks for Internal Medicine with Dr. Andre Mansoor
Next

1.26 Lesson From an ASH Abstract, Behind the Scenes of a Residency Program with Dr. Sima Desai